Liver function study tests drug processing in 29 volunteers

NCT ID NCT05882032

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the drug LY3502970 enters the bloodstream and leaves the body in people with different levels of liver function. 29 participants, including healthy volunteers and those with mild to severe liver impairment, took a single dose. The goal was to understand dosing safety, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970 (an oral drug)
What this could lead to: If successful, this study will help determine safe dosing of LY3502970 for people with liver problems, potentially guiding future treatment use.
What could go wrong: This is a very early phase 1 study with only 29 participants, focused on drug processing, not treatment effects. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC INSUFFICIENCY

Contacts and locations

Locations

Clinical Pharmacology of Miami

Miami, Florida, 33014, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Pinnacle Clinical Research

San Antonio, Texas, 78229, United States
Texas Liver Institute

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.